SCHEMBL335484

SCHEMBL335484

CCN(CC)c1ccc(C(=O)NC(c2ccccc2)C(O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
IKBKB O14920 1/20 0.43
CNR2 P34972 1/20 0.42
ABL1 P00519 1/20 0.40
FABP6 P51161 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HCRTR1 O43613 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
F9 P00740 1/20 0.40
F7 P08709 1/20 0.40
MAPK1 P28482 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
CHEK2 O96017 1/20 0.39
TYMS P04818 2/20 0.38
NR2E3 Q9Y5X4 1/20 0.38
GBA1 P04062 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337002 0.93 MAPT (0.41) MAPTIKBKBCNR2SMN1; SMN2HCRTR1
SCHEMBL335968 0.92 MAPT (0.41) MAPTIKBKBCNR2SMN1; SMN2F9
SCHEMBL336687 0.91 MAPT (0.39) MAPTIKBKBSMN1; SMN2F9F7
SCHEMBL335526 0.91 ABL1 (0.42) MAPTABL1FABP6SMN1; SMN2F9
SCHEMBL335848 0.91 MCHR1 (0.42) MAPTIKBKBSMN1; SMN2F9F7
SCHEMBL335303 0.90 MAPT (0.40) MAPTIKBKBSMN1; SMN2F9F7
SCHEMBL335191 0.90 MAPT (0.45) MAPTIKBKBCNR2ABL1FABP6
SCHEMBL336055 0.89 MAPT (0.46) MAPTIKBKBSMN1; SMN2F9F7
SCHEMBL335501 0.89 NPC1 (0.43) MAPTABL1FABP6SMN1; SMN2F9
SCHEMBL335524 0.89 NR2E3 (0.43) MAPTIKBKBSMN1; SMN2HCRTR1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885IKBKB 230/4885CNR2 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.